BDA MDI HFO

BDA MDI HFO is a fixed-dose combination drug-device product containing budesonide (an inhaled corticosteroid) and albuterol (a short-acting β2-adrenergic receptor agonist) delivered via a metered dose inhaler (MDI) that uses hydrofluoroolefin (HFO) as the propellant. This formulation is being developed as an as-needed rescue therapy for asthma, aiming to provide rapid symptom relief through albuterol while simultaneously reducing airway inflammation with budesonide. The use of HFO represents an environmentally friendlier alternative to traditional hydrofluoroalkane (HFA) propellants. The primary indication under investigation is asthma, where the combination seeks to reduce severe exacerbations by addressing both bronchoconstriction and underlying inflammation in response to worsening symptoms[1][2][3][4].

Other names

budesonide/albuterol metered dose inhaler with hydrofluoroolefin propellantBDA inhaler with new propellant